Sunday, March 26, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Infectious Diseases

Naval Medical Center San Diego Administers Hospital’s First mAb Treatment to COVID-19 Patient

by Global Biodefense Staff
January 30, 2021
Naval Medical Center San Diego Administers Hospital’s First mAb Treatment to COVID-19 Patient

Lt. Cmdr. Raben Talvo, Naval Medical Center San Diego's (NMCSD) Office of Clinical Quality department head, administers the hospital’s first monoclonal antibody (mAb) treatment, bamlanivimab, to a COVID-19-positive patient Jan. 26. Credit: Harley Sarmiento

Naval Medical Center San Diego (NMCSD) administered the hospital’s first monoclonal antibody (mAb) treatment to a COVID-19-positive patient Jan. 26. The intravenous infusion is

Bamlanivimab is approved for emergency use authorization (EUA) guidance from the U.S. Food and Drug Administration (FDA) for the treatment of mild to moderate COVID-19 in patients 12 years or older with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19.

“The treatment is infused via IV, and [is designed] to decrease or slow down the replication of the virus in the patient,” said Lt. Cmdr. Raben Talvo, NMCSD’s Office of Clinical Quality department head. “We’re preventing the patient’s symptoms from getting worse, thus lessening the strain on our healthcare facility.”

Talvo, a registered nurse, administered the mAb treatment and adhered to the FDA’s high-risk patient guidelines.

“[The treatment] is a one time, one hour infusion plus one hour of observation,” said Talvo. “It’s key for us to identify potential patients who have not only tested positive for COVID-19, but have experienced an onset of symptoms within 10 days before we can offer this treatment. These potential patients would have had mild to moderate symptoms for 10 days or less, and this treatment is not for people who are currently admitted into a hospital due to their symptoms.”

Lt. Cmdr. Alison Lane, NMCSD’s Infectious Diseases division head, said the hospital offers the mAb treatment infusion to all eligible patients, but the decision to proceed is reached via an individualized, shared decision-making process with each patient.
“Getting the mAb treatment to the right patients at the right time to safely maximize potential benefits is logistically challenging,” said Lane.

Capt. Juliann Althoff, NMCSD’s chief medical officer with a background in preventative medicine and a public health physician by trade, said the mAb therapy is currently being administered through local health systems and other military training facilities.
“It’s given as an outpatient infusion with the goal of minimizing severe illness and hospitalizations,” said Althoff. “In addition to the public health essentials of physical distancing and mask-wearing, and the upcoming rollouts of vaccines, [mAb therapy] is an additional option we can now offer our beneficiaries.”

Lane echoed her colleagues’ thoughts that preventing hospital admissions for COVID-19 is not only beneficial to individual patients, but also reduces strain on this hospital and the healthcare system as a whole.

Article adapted from original story by Jacob L. Greenberg, Naval Medical Center San Diego

Tags: COVID CountermeasuresCOVID-19Editor PickMedicine-HealthSARS-CoV-2Therapeutic Antibodies

Related Posts

DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies
Medical Countermeasures

NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies

January 12, 2023
Load More

Latest News

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy